Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myelomaMichèle Cavo, Antonio Palumbo, Lucia Pantani et al.|Blood|2012Cited by 310
Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma: Results From a Randomized Phase 3 StudyMichèle Cavo, Michele Baccarani, Giulia Perrone et al.|Blood|2010Cited by 12
Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life ApplicationRoberto Mina, Elena Zamagni, Carmine Liberatore et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 1